Literature DB >> 34843656

Dysregulation of the sensory and regulatory pathways controlling cellular iron metabolism in unilateral obstructive nephropathy.

James A Votava1, Shannon R Reese2, Kathryn M Deck1, Christopher P Nizzi1, Sheila A Anderson1, Arjang Djamali2,3, Richard S Eisenstein1,4.   

Abstract

Chronic kidney disease involves disturbances in iron metabolism including anemia caused by insufficient erythropoietin (EPO) production. However, underlying mechanisms responsible for the dysregulation of cellular iron metabolism are incompletely defined. Using the unilateral ureteral obstruction (UUO) model in Irp1+/+ and Irp1-/- mice, we asked if iron regulatory proteins (IRPs), the central regulators of cellular iron metabolism and suppressors of EPO production, contribute to the etiology of anemia in kidney failure. We identified a significant reduction in IRP protein level and RNA binding activity that associates with a loss of the iron uptake protein transferrin receptor 1 (TfR1), increased expression of the iron storage protein subunits H- and L-ferritin, and a low but overall variable level of stainable iron in the obstructed kidney. This reduction in IRP RNA binding activity and ferritin RNA levels suggests the concomitant rise in ferritin expression and iron content in kidney failure is IRP dependent. In contrast, the reduction in the Epo mRNA level in the obstructed kidney was not rescued by genetic ablation of IRP1, suggesting disruption of normal hypoxia-inducible factor (HIF)-2α regulation. Furthermore, reduced expression of some HIF-α target genes in UUO occurred in the face of increased expression of HIF-α proteins and prolyl hydroxylases 2 and 1, the latter of which is not known to be HIF-α mediated. Our results suggest that the IRP system drives changes in cellular iron metabolism that are associated with kidney failure in UUO but that the impact of IRPs on EPO production is overridden by disrupted hypoxia signaling.NEW & NOTEWORTHY This study demonstrates that iron metabolism and hypoxia signaling are dysregulated in unilateral obstructive nephropathy. Expression of iron regulatory proteins (IRPs), central regulators of cellular iron metabolism, and the iron uptake (transferrin receptor 1) and storage (ferritins) proteins they target is strongly altered. This suggests a role of IRPs in previously observed changes in iron metabolism in progressive renal disease. Hypoxia signaling is disrupted and appeared to dominate the action of IRP1 in controlling erythropoietin expression.

Entities:  

Keywords:  erythropoietin; iron metabolism; iron regulatory proteins; prolyl hydroxylase; renal failure

Mesh:

Substances:

Year:  2021        PMID: 34843656      PMCID: PMC8742730          DOI: 10.1152/ajprenal.00537.2020

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  83 in total

1.  Inhibition of Nrf2 alters cell stress induced by chronic iron exposure in human proximal tubular epithelial cells.

Authors:  S E G van Raaij; R Masereeuw; D W Swinkels; R P L van Swelm
Journal:  Toxicol Lett       Date:  2018-06-28       Impact factor: 4.372

2.  Iron deposition in renal biopsy specimens from patients with kidney diseases.

Authors:  H Wang; K Nishiya; H Ito; T Hosokawa; K Hashimoto; T Moriki
Journal:  Am J Kidney Dis       Date:  2001-11       Impact factor: 8.860

3.  MicroRNA-148b regulates megalin expression and is associated with receptor downregulation in mice with unilateral ureteral obstruction.

Authors:  Lu Wen; Pia K Andersen; Dina M U Husum; Rikke Nørregaard; Zhanzheng Zhao; Zhangsuo Liu; Henrik Birn
Journal:  Am J Physiol Renal Physiol       Date:  2017-03-22

4.  Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.

Authors:  Wanja M Bernhardt; Michael S Wiesener; Paul Scigalla; James Chou; Roland E Schmieder; Volkmar Günzler; Kai-Uwe Eckardt
Journal:  J Am Soc Nephrol       Date:  2010-11-29       Impact factor: 10.121

5.  Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition.

Authors:  Debra F Higgins; Kuniko Kimura; Wanja M Bernhardt; Nikita Shrimanker; Yasuhiro Akai; Bernd Hohenstein; Yoshihiko Saito; Randall S Johnson; Matthias Kretzler; Clemens D Cohen; Kai-Uwe Eckardt; Masayuki Iwano; Volker H Haase
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

6.  Lysosomal iron accumulation in diabetic nephropathy.

Authors:  B J Nankivell; Y C Tay; R A Boadle; D C Harris
Journal:  Ren Fail       Date:  1994       Impact factor: 2.606

7.  Tubular expression of heat-shock protein 27 inhibits fibrogenesis in obstructive nephropathy.

Authors:  Aparna Vidyasagar; Shannon R Reese; Omeed Hafez; Ling-Jin Huang; William F Swain; Lynn M Jacobson; Jose R Torrealba; Pierre-Emmanuel Chammas; Nancy A Wilson; Arjang Djamali
Journal:  Kidney Int       Date:  2012-09-12       Impact factor: 10.612

8.  Tubular iron deposition and iron handling proteins in human healthy kidney and chronic kidney disease.

Authors:  Sanne van Raaij; Rachel van Swelm; Karlijn Bouman; Maaike Cliteur; Marius C van den Heuvel; Jeanne Pertijs; Dominic Patel; Paul Bass; Harry van Goor; Robert Unwin; Surjit Kaila Srai; Dorine Swinkels
Journal:  Sci Rep       Date:  2018-06-19       Impact factor: 4.379

9.  FBXL5 Regulates IRP2 Stability in Iron Homeostasis via an Oxygen-Responsive [2Fe2S] Cluster.

Authors:  Hui Wang; Hui Shi; Malini Rajan; Elizabeth R Canarie; Seoyeon Hong; Daniele Simoneschi; Michele Pagano; Matthew F Bush; Stefan Stoll; Elizabeth A Leibold; Ning Zheng
Journal:  Mol Cell       Date:  2020-03-02       Impact factor: 17.970

10.  Hypoxia-inducible factor signaling in the development of kidney fibrosis.

Authors:  Volker H Haase
Journal:  Fibrogenesis Tissue Repair       Date:  2012-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.